EFFECT OF LOVASTATIN ON SERUM OSTEOPROTEGERIN LEVEL IN TYPE 2 DIABETIC NEPHROPATHY

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

NEZAMI N.; ASGHARI M.; SAFA J.; BAGHERI ASL M.M.; SALARI B.; GHORASHI S.

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: JOURNAL OF BABOL UNIVERSITY OF MEDICAL SCIENCES (JBUMS) Year:2012 | Volume:14 | Issue:4 (67) Page(s): 61-70

Download Full-Text

Persian Verion

View:

747

Download:

Cites:

Information Journal Paper

Title

EFFECT OF LOVASTATIN ON SERUM OSTEOPROTEGERIN LEVEL IN TYPE 2 DIABETIC NEPHROPATHY

Author(s)

Keywords

OSTEOPROTEGERINQ2

RANK LIGANDQ2

DIABETIC NEPHROPATHYQ2

LOVASTATINQ2

Abstract

BACKGROUND AND OBJECTIVE: OSTEOPROTEGERIN (OPG), a glycoprotein is a member of the tumor necrotizing factor alpha receptor super-family. By considering the possible role of OPG in cardiovascular disease (CVD), higher incidence of CVD in patients with type 2 DIABETIC NEPHROPATHY (T2DN), and anti-atherosclerotic effects of statins, the present study aimed to investigate the effects of LOVASTATIN on serum levels of OPG, and soluble receptor activator of nuclear factor-Kb ligand (sRANKL) in people with T2DN.METHODS: During the present quasi clinical trial, 30 male adult patients with type 2 DIABETIC NEPHROPATHY were studied. LOVASTATIN, 20 mg/d was administrated for 90 days. Serum levels of OPG and sRANKL were measured using commercial ELISA kits at baseline, after 90 days of intervention, and after 30 days of withdrawal of LOVASTATIN.FINDINGS: Serum level of OPG was significantly increased (10.76±16.44) and decreased (7.38±11.98) during 90 days of intervention and 30 days of withdrawal periods, respectively (p<0.002), while sRANKL level was significantly decreased (1192.08±578.20) and increased (4418.67±2124.66) during the same periods, respectively (p<0.001).CONCLUSION: These results indicate decreased risk of atherosclerosis and vascular calcification following LOVASTATIN administration.

Cites

No record.

References

No record.

Cite

APA: Copy

NEZAMI, N., ASGHARI, M., SAFA, J., BAGHERI ASL, M.M., SALARI, B., & GHORASHI, S.. (2012). EFFECT OF LOVASTATIN ON SERUM OSTEOPROTEGERIN LEVEL IN TYPE 2 DIABETIC NEPHROPATHY. JOURNAL OF BABOL UNIVERSITY OF MEDICAL SCIENCES (JBUMS), 14(4 (67)), 61-70. SID. https://sid.ir/paper/73384/en

Vancouver: Copy

NEZAMI N., ASGHARI M., SAFA J., BAGHERI ASL M.M., SALARI B., GHORASHI S.. EFFECT OF LOVASTATIN ON SERUM OSTEOPROTEGERIN LEVEL IN TYPE 2 DIABETIC NEPHROPATHY. JOURNAL OF BABOL UNIVERSITY OF MEDICAL SCIENCES (JBUMS)[Internet]. 2012;14(4 (67)):61-70. Available from: https://sid.ir/paper/73384/en

IEEE: Copy

N. NEZAMI, M. ASGHARI, J. SAFA, M.M. BAGHERI ASL, B. SALARI, and S. GHORASHI, “EFFECT OF LOVASTATIN ON SERUM OSTEOPROTEGERIN LEVEL IN TYPE 2 DIABETIC NEPHROPATHY,” JOURNAL OF BABOL UNIVERSITY OF MEDICAL SCIENCES (JBUMS), vol. 14, no. 4 (67), pp. 61–70, 2012, [Online]. Available: https://sid.ir/paper/73384/en

Related Journal Papers